Medivisor announces Medicaid approval for Albumax

Albumax has been approved under code B4155 as an enteral product. The approval is significant in that it allows for Medicaid reimbursement of costs for eligible patients using Albumax.

Under a recently announced agreement with Cura Pharmaceutical, Medivisor is responsible for marketing and sales of Albumax, a whey protein isolate formula that makes it easy for kidney disorder patients to reach their daily requirements of high quality protein in their diet.

Dino Luzzi, CEO of Medivisor, said: “Medicaid approval is an extremely important component in our marketing initiative for the national launch of Albumax. Medicaid acceptance for Albumax certainly strengthens the interest in the product, and increases the willingness of providers and patients to use Albumax to increase blood albumin levels in kidney disorder patients.”